Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 9INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Conditions

Leiomyoma 2

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Progestins × Clear all
NCT01156857 2016-01-15

PEARLIII

PregLem SA

Phase 3 Completed
209 enrolled

Leiomyoma

NCT01252069 2016-01-13

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)

PregLem SA

Phase 3 Completed
132 enrolled

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡